Loading
A phase 2 trial of Filgrastim and Oprelvekin in Breast cancer, Neuroblastoma and Ovarian cancer, run by Fred Hutchinson Cancer Center, completed.
Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors is a phase 2 interventional study registered as NCT00004157 by Fred Hutchinson Cancer Center, started 2000-08 and reaching its primary completion in 2002-04. Interventions recorded: filgrastim, recombinant interleukin-11. Conditions recorded: Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor.
Linked to the drug Oprelvekin because the registry names it among its interventions and Breast cancer, Neuroblastoma and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Oprelvekin and the tag pipeline.
Shares Filgrastim (G-CSF), Breast cancer (all types) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Neuroblastoma (paediatric), Ovarian cancer and the tag pipeline.
Shares Neuroblastoma (paediatric) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.